JAKARTA — Type 2 diabetes mellitus is a chronic global health challenge often accompanied by debilitating long-term complications. Among the most prevalent and dangerous of these is peripheral neuropathy, a form of nerve damage that frequently impacts the lower extremities. This condition robs patients of tactile sensitivity in their feet, rendering them vulnerable to undetected pressures, continuous friction, and minor abrasions. Left unmonitored, these microscopic injuries can rapidly escalate into severe diabetic ulcers, deep tissue infections, and, in worst-case scenarios, lower-limb amputations. Recognizing this critical clinical gap, a multidisciplinary team of undergraduate students from Universitas Gadjah Mada (UGM) in Yogyakarta has engineered a pioneering technological solution: Glucowrap, an intelligent "smart sandal" system designed to detect and evaluate the early risks of diabetic foot complications in real time. Main Facts The Glucowrap project is an intersection of biomedical engineering, nursing science, and digital health designed specifically to safeguard diabetes patients from the silent threat of neuropathic foot ulcers. The Core Innovation: Glucowrap functions as an open-toe smart sandal embedded with advanced micro-sensors capable of monitoring physical pressure, surface temperature, and local humidity levels concurrently as the user walks. The Development Team: The project was conceptualized and brought to life under the Student Creativity Program in the field of Artificial Creation (PKM-KC) at UGM. The team is spearheaded by Rina Putri Cahyati, an undergraduate student from the Faculty of Nursing (Ilmu Keperawatan), alongside four cross-disciplinary student innovators. Academic Guidance: The student collective operates under the direct mentorship and supervision of Ir. Ma’un Budiyanto, S.T., M.T., IPU., a distinguished faculty member and engineering expert at UGM. Data Integration: Sensor outputs are transmitted seamlessly to a mobile application interface, categorizing patient risk profiles into three distinct tiers: normal, mild risk, and high risk. This empowers both patients and their families to maintain continuous awareness of foot health without requiring specialized clinical equipment. Ergonomics and Safety: Prioritizing biocompatibility and comfort, the sandal incorporates bamboo fiber biotextiles treated with chitosan for natural antibacterial properties, paired with low-intensity thermal and micro-vibration stimulation features. Clinical Validation: The device has already successfully navigated rigorous ethical clearances from the Medical and Health Research Ethics Committee (MHREC) of the Faculty of Medicine, Public Health, and Nursing (FK-KMK UGM) and has undergone initial testing phases on Type 2 diabetes patients at the Korpagama Clinic in Yogyakarta. Chronology of Development The journey toward the creation of Glucowrap spans months of intensive research, cross-faculty collaboration, and meticulous laboratory testing. Phase 1: Problem Identification and Ideation The initiative began when Rina Putri Cahyati and her team identified a recurring pattern in clinical observations of diabetes patients: the insidious nature of peripheral neuropathy. Because patients lose the physical capacity to feel pain or discomfort in their feet, standard daily activities—such as walking around the house or wearing conventional footwear—frequently result in unnoticed trauma. The team realized that traditional preventative measures, which rely heavily on visual inspections by healthcare professionals or subjective patient reports, were insufficient for round-the-clock protection. Phase 2: Cross-Disciplinary Team Formation and Design To tackle a challenge spanning medicine, electronics, materials science, and software engineering, Rina assembled a diverse team of peers from various faculties within UGM. Together, they drafted the blueprint for a wearable device that was not only technologically sophisticated but also comfortable, aesthetically unobtrusive, and financially viable. They selected an open-toe sandal design to maximize airflow and minimize unnecessary friction points common in enclosed shoes. Phase 3: Hardware and Software Integration During the prototyping stage, the engineering subsection integrated ultra-thin pressure sensors, temperature monitors, and humidity detectors into the sole of the sandal. Simultaneously, software developers constructed a companion mobile application capable of interpreting the raw telemetry data streaming from the hardware. They programmed an algorithm to classify the incoming data into clear, actionable risk categories: Normal, Mild Risk, and High Risk. Phase 4: Ethical Clearance and Clinical Trials Before exposing human subjects to the prototype, the team submitted their research design to the Komite Etik FK-KMK UGM. Upon receiving official ethical approval, they partnered with the Korpagama Clinic in Yogyakarta to conduct controlled pilot trials involving actual Type 2 diabetes patients. During these trials, patients underwent baseline foot sensitivity screenings before stepping into the Glucowrap sandals. They were asked to walk for a standardized duration of 15 minutes while the sensors recorded biomechanical and environmental data. Afterward, participants completed qualitative evaluations regarding the device’s physical comfort, ease of application use, and overall wearability. Supporting Data and Technological Specifications The efficacy of Glucowrap lies in its sophisticated blending of material science, sensor technology, and patient-centric ergonomics. +-----------------------------------------------------------------+ | GLUCOWRAP ARCHITECTURE | +-----------------------------------------------------------------+ | [Hardware Layer] | | - Pressure Sensors -> Detects localized plantar overpressure| | - Temperature Sensors -> Identifies early inflammation zones | | - Humidity Sensors -> Monitors microclimate moisture levels | +-----------------------------------------------------------------+ │ (Real-time Data Stream) ▼ +-----------------------------------------------------------------+ | [Software Layer] | | - Mobile App Interface -> Displays instant risk categorization | | - Risk Tiers -> Normal | Mild Risk | High Risk | +-----------------------------------------------------------------+ │ (User Awareness) ▼ +-----------------------------------------------------------------+ | [Ergonomic & Therapeutic Layer] | | - Bamboo Fiber Biotextiles -> Breathable, sustainable fabric | | - Chitosan Treatment -> Natural antibacterial defense | | - Micro-vibration -> Enhances local blood circulation | +-----------------------------------------------------------------+ 1. Multi-Parameter Sensor Array Peripheral neuropathy alters how the foot interacts with the ground. By continuously tracking pressure distribution, Glucowrap flags hotspots where excessive plantar pressure could trigger a blister or ulcer. Simultaneously, localized temperature tracking can spot subtle thermal spikes indicative of deep-tissue inflammation or early-stage infection before external symptoms appear. Humidity tracking addresses the secondary risk of excessive moisture, which softens the skin and accelerates fungal or bacterial growth. 2. Advanced Material Science To prevent secondary infections—a major hazard for diabetic patients whose immune responses are often compromised—the inner lining of the sandal utilizes sustainable bamboo fiber biotextiles. This material is chemically treated with chitosan, a natural polysaccharide derived from chitin found in crustacean shells, celebrated for its potent broad-spectrum antibacterial and wound-healing properties. 3. Therapeutic Micro-Stimulation Beyond passive monitoring, Glucowrap incorporates active comfort features. The footwear is equipped with low-intensity thermal and micro-vibration stimulation systems designed to gently encourage local micro-circulation in the feet, counteracting the circulatory sluggishness frequently experienced by diabetic individuals. Official Responses and Perspectives The unveiling of Glucowrap has drawn widespread attention and praise from academic circles, healthcare advocates, and the student creators themselves. Perspective from the Lead Researcher Rina Putri Cahyati emphasized that while the technology represents a major leap forward in proactive health management, it is designed to complement—not replace—professional medical oversight. "Peripheral neuropathy can severely diminish sensitivity in the lower extremities, meaning patients often remain entirely oblivious to dangerous pressure points, friction, or evolving micro-traumas on their skin," Rina explained during an interview published via official UGM channels. "If these subtle warning signs are not recognized and addressed immediately, the condition can easily deteriorate into chronic, hard-to-heal wounds. Glucowrap is currently undergoing extensive refinement. We must stress that this device is not intended to supersede formal clinical examinations or professional medical treatments. Instead, it is engineered to serve as an intelligent, accessible home-monitoring assistant for everyday life." Institutional and Faculty Support Under the mentorship of Ir. Ma’un Budiyanto, S.T., M.T., IPU., the student project has benefited immensely from institutional guidance, bridging the gap between theoretical classroom engineering and practical, life-saving healthcare solutions. Faculty leaders have underscored the project as a prime example of UGM’s ongoing commitment to fostering human-centric innovations that address real-world socio-economic and public health challenges in Indonesia and beyond. Implications and Future Outlook The broader implications of the Glucowrap innovation extend far beyond the walls of an academic competition. If successfully commercialized and scaled, smart wearable health technologies like Glucowrap could fundamentally transform diabetes self-management paradigms, particularly in developing nations where healthcare access can be geographically or economically constrained. 1. Shifting from Reactive to Preventive Healthcare Historically, diabetic foot care has been overwhelmingly reactive. Patients typically visit a physician only after an ulcer has formed, developed necrosis, or begun threatening systemic health. By providing an intuitive, real-time feedback loop via smartphone applications, Glucowrap shifts the clinical paradigm toward early detection. Patients are alerted the moment a pressure or temperature anomaly is logged, allowing them to adjust their footwear, rest their feet, or consult a physician long before tissue breakdown occurs. 2. Alleviating the Socioeconomic Burden of Amputations Diabetic foot complications are among the leading causes of non-traumatic lower-extremity amputations globally. The emotional, physical, and financial toll of such procedures on patients and their families is immense, often accompanied by long-term disability and loss of productivity. Affordable, home-based screening tools have the potential to drastically lower amputation rates, thereby reducing hospital readmissions and easing the financial burden on national health insurance schemes like Indonesia’s BPJS Kesehatan. 3. Future Development Goals Looking ahead, Rina and her multidisciplinary team plan to expand their clinical trial cohorts, gather longitudinal data to fine-tune the sensor algorithms, and optimize manufacturing costs. Their ultimate vision is to see Glucowrap evolve into a fully autonomous, highly affordable, and medically certified consumer health device available to communities nationwide, ensuring that patients living with diabetes can walk through life with greater confidence, safety, and independence. Post navigation The Science of Sleep: Does Drinking Milk Before Bed Really Improve Sleep Quality?
